Ligand Pharmaceuticals has made its second major acquisition in 2024, agreeing a $100 million deal to buy Austria’s Apeiron Biologics and a royalty stream for brain cancer drug Qarziba.
Essential Pharma has bought fellow UK drugmaker Renaissance Pharma, adding its first development-stage drug candidate, a therapy for hard-to-treat rare cancer neuroblastom
Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously rejected its brain cancer therapy 131I-omburtamab in 16 to 0 vote.
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.